GlassScriptPhysician profile
Andres M Fraga
NPI 1508330150
$4,313.35
in general payments reported to CMS, 2019-2025
21 companies · $49.01 in 2025
The $49.01 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,165 · 2022: $1,379 · 2023: $618 · 2024: $102 · 2025: $49.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $769.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $713.35 | 2021-2023 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $570.87 | 2021-2023 | |
| Abbvie INC. | $468.21 | 2021-2023 | |
| Neurocrine Biosciences, INC. | $395.97 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $353.14 | 2021-2024 | Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $331.50 | 2021-2023 | Rexulti, Abilify Maintena, Nuedexta |
| Alkermes, INC. | $269.73 | 2021-2023 | Lybalvi, Aristada |
| Supernus Pharmaceuticals, INC. | $231.80 | 2022-2025 | Qelbree, Qelbree |
| Sunovion Pharmaceuticals INC. | $218.50 | 2021-2022 | |
| Lundbeck LLC | $172.20 | 2021-2023 | Rexulti |
| Eisai INC. | $133.83 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $90.44 | 2021-2023 | Trintellix |
| Merck Sharp & Dohme LLC | $87.36 | 2021-2023 | Belsomra |
| Jazz Pharmaceuticals INC. | $62.62 | 2021 | |
| Bausch Health US, LLC | $50.46 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $50.37 | 2021 | |
| Almatica Pharma LLC | $30.57 | 2022 | |
| Vanda Pharmaceuticals INC. | $28.08 | 2023 | Fanapt, Hetlioz |
| Corium, LLC | $21.98 | 2023-2024 | Azstarys |
| Indivior INC. | $19.63 | 2022 | |
| Idorsia Pharmaceuticals US INC | $12.74 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andres Fraga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.